Moghetti P, Castello R, Tosi F, Zenti M G, Magnani C, Bolner A, Perobelli L, Muggeo M
Department of Metabolic Diseases, University of Verona, Italy.
J Clin Endocrinol Metab. 1994 Jan;78(1):169-73. doi: 10.1210/jcem.78.1.8288700.
To evaluate the impact of hyperthyroidism on the counterregulatory response to hypoglycemia, eight hyperthyroid and eight sex-, age-, and body mass index-matched healthy women were given an iv insulin bolus (0.1 U/kg BW), and blood was drawn from 0-120 min for glucose, epinephrine, norepinephrine, glucagon, GH, ACTH, and cortisol measurements. In the basal state plasma glucose, GH, and cortisol levels were similar in the two groups, whereas plasma glucagon and ACTH were increased (135 +/- 17 vs. 80 +/- 10 ng/L and 6.4 +/- 1.5 vs. 2.6 +/- 0.4 pmol/L, respectively; both P < 0.025), and plasma catecholamines were reduced [epinephrine, 142 +/- 25 vs. 371 +/- 71 pmol/L (P < 0.025); norepinephrine, 0.41 +/- 0.07 vs. 1.41 +/- 0.12 nmol/L (P < 0.001)] in hyperthyroid patients. After insulin injection, plasma glucose similarly declined in the two groups (nadir, 1.5 +/- 0.2 vs. 1.6 +/- 0.2 mmol/L). Conversely, recovery from hypoglycemia was significantly faster in the hyperthyroid patients. In this respect, it is noteworthy that the plasma glucagon response had remarkably increased in the latter (peak, 444 +/- 56 vs. 198 +/- 17 ng/L; P < 0.005). On the other hand, the epinephrine responses were similar in the two groups, whereas norepinephrine levels remained consistently lower (peak, 0.97 +/- 0.20 vs. 2.61 +/- 0.24 nmol/L; P < 0.001), and the GH increase was severely impaired (peak, 10.6 +/- 1.9 vs. 29.6 +/- 6.2 micrograms/L; P < 0.01) in hyperthyroid patients. Plasma ACTH remained slightly higher in hyperthyroid subjects, but there were no substantial differences in the cortisol response between the two groups. In conclusion, hyperthyroidism affects plasma levels of several counterregulatory hormones, either in the fasting state or after insulin-induced hypoglycemia, with increased efficiency of plasma glucose recovery from hypoglycemia.
为评估甲状腺功能亢进对低血糖反调节反应的影响,对8名甲状腺功能亢进女性和8名年龄、性别、体重指数相匹配的健康女性静脉注射胰岛素推注(0.1 U/kg体重),并在0至120分钟内采集血液,检测血糖、肾上腺素、去甲肾上腺素、胰高血糖素、生长激素、促肾上腺皮质激素和皮质醇水平。在基础状态下,两组的血浆葡萄糖、生长激素和皮质醇水平相似,而甲状腺功能亢进患者的血浆胰高血糖素和促肾上腺皮质激素升高(分别为135±17 vs. 80±10 ng/L和6.4±1.5 vs. 2.6±0.4 pmol/L;均P<0.025),血浆儿茶酚胺降低[肾上腺素,142±25 vs. 371±71 pmol/L(P<0.025);去甲肾上腺素,0.41±0.07 vs. 1.41±0.12 nmol/L(P<0.001)]。注射胰岛素后,两组血浆葡萄糖同样下降(最低点,1.5±0.2 vs. 1.6±0.2 mmol/L)。相反,甲状腺功能亢进患者从低血糖中恢复明显更快。在这方面,值得注意的是,后者的血浆胰高血糖素反应显著增加(峰值,444±56 vs. 198±17 ng/L;P<0.005)。另一方面,两组的肾上腺素反应相似,而甲状腺功能亢进患者的去甲肾上腺素水平持续较低(峰值,0.97±0.20 vs. 2.61±0.24 nmol/L;P<0.001),生长激素升高严重受损(峰值,10.6±1.9 vs. 29.6±6.2 μg/L;P<0.01)。甲状腺功能亢进患者的血浆促肾上腺皮质激素仍略高,但两组之间的皮质醇反应无显著差异。总之,甲状腺功能亢进在空腹状态或胰岛素诱导的低血糖后会影响几种反调节激素的血浆水平,提高从低血糖中恢复血浆葡萄糖的效率。